Document is current
Any future updates will be listed below
-
Authors
Parenti, Giancarlo https://orcid.org/0000-0002-6287-5748
Fecarotta, Simona
Alagia, Marianna
Attaianese, Federica
Verde, Alessandra
Tarallo, Antonietta
Gragnaniello, Vincenza
Ziagaki, Athanasia
Guimaraes, Maria Jose’
Aguiar, Patricio
Hahn, Andreas
Azevedo, Olga
Donati, Maria Alice
Kiec-Wilk, Beata
Scarpa, Maurizio
van der Beek, Nadine A. M. E.
Del Toro Riera, Mireja
Germain, Dominique P.
Huidekoper, Hidde
van den Hout, Johanna M. P.
van der Ploeg, Ans T.
,
Baric, Ivo
Batzios, Spyros
Belmatoug, Nadia
Bordugo, Andrea
Bosch, Annet M.
Brassier, Anais
Burlina, Alberto
Cassiman, David
Chabrol, Brigitte
Chronopoulou, Efstathia
Couce-Pico, Maria Luz
Darin, Niklas
Das, Anibh M.
Debray, Francois G.
Deegan, Patrick
de Abreu Freire Diogo Matos, Luisa M.
De Las Heras Montero, Javier
Di Rocco, Maja
Dobbelaere, Dries
Eyskens, Francois
Ferreira, Ana
Gaspar, Ana M.
Gasperini, Serena
López, Antonio González-Meneses
Grosso, Salvatore
Guffon-Fouilhoux, Nathalie
Hennermann, Julia
Hiwot, Tarekegn G.
Jones, Simon
Kingma, Sandra
Komninaka, Veroniki
Martín-Hernández, Elena
Martins, Esmeralda
Miclea, Diana
Pfliegler, György
Rodrigues, Esmeralda
Rokicki, Dariusz
Roland, Dominique
Rutsch, Frank
Salviati, Alessandro
Tournev, Ivailo
Ullrich, Kurt
van Hasselt, Peter M.
Vijay, Suresh
Weinhold, Natalie
Witters, Peter
Zeman, Jiri
- License Information
-
More Information
Article History
Received: 2 January 2024
Accepted: 18 September 2024
First Online: 1 November 2024
Declarations
:
: Not applicable.
: Not applicable.
: GP has received funding for research and clinical trials and advisory fees from Sanofi-Genzyme, Amicus Therapeutics, Orchard, Synageva/Alexion, BioMarin, Denali, Takeda. SF has received honoraria, consulting fees, speaker fees and travel reimbursement. From Sanofi, Amicus, Alexion, Chiesi. MJG has received educational and research grants from Sanofi Genzyme. PRTA received grant/research support from Takeda, and speaker/travel. honoraria from Takeda, Sanofi-Genzyme, BioMarin, Ultragenyx, Alexion, Amicus Therapeutics, and Chiesi.. OA has received educational/research grants from Shire Human Genetic Therapies/Takeda and travel/accommodation support for conferences from Shire Human Genetic. Therapies/Takeda, Amicus and Sanofi Genzyme. MAD received travel grants for scientific meetings and honoraria for speaking. engagements from Shire International, Sanofi Genzyme and BioMarin. MS has received honoraria, research and travel grants from Alexion, BioMarin. Pharmaceutical Inc., Chiesi, Sanofi Genzyme, Shire, Ultragenix and Sangamo. NAMEvdeB has received consulting fees and travel reimbursement from Sanofi andAmicus Therapeutics and received funding for research, clinical trials, and advisory fees from Sanofi. MDTR has received consulting fees and speaker honoraria, travel expenses, and congress fees from Biomarin, Sanofi Genzyme, Takeda,and has participated in trials sponsored by Orphazyme, Takeda, Vtesse-Sucampo Mallinckrodt). DPG has received consulting honoraria from Chiesi, Idorsia Pharmaceuticals, Sanofi and Takeda, and speaker honoraria and travel support from Sanofi and Takeda. HH reports advisory board fees, speaker fee, and a clinical trial agreement from BioMarin. JMPvdH received funding for research, clinical trials, and advisory fees from Sanofi-Genzyme, Amicus Therapeutics, BioMarin, Sarepta, Denali, Takeda and Chiesi. ATvdP has received grant for clinical trials conduction from Amicus Therapeutics andSanofi-Genzyme. MA, FA, AV, AT, VG, AZ, AH, BKW have no conflicts of interest to declare.
